Bioventus Inc. (NYSE:BVS) Shares Sold by Nantahala Capital Management LLC

Nantahala Capital Management LLC cut its stake in Bioventus Inc. (NYSE:BVS - Free Report) by 7.4% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 4,026,809 shares of the company's stock after selling 324,061 shares during the period. Bioventus comprises about 1.8% of Nantahala Capital Management LLC's holdings, making the stock its 7th largest holding. Nantahala Capital Management LLC owned about 4.96% of Bioventus worth $42,281,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors and hedge funds have also recently bought and sold shares of BVS. Northern Trust Corp boosted its stake in shares of Bioventus by 7.3% in the 4th quarter. Northern Trust Corp now owns 345,916 shares of the company's stock valued at $3,632,000 after buying an additional 23,523 shares during the period. Oberweis Asset Management Inc. lifted its stake in Bioventus by 17.8% in the fourth quarter. Oberweis Asset Management Inc. now owns 601,714 shares of the company's stock worth $6,318,000 after acquiring an additional 90,800 shares during the last quarter. Price T Rowe Associates Inc. MD grew its holdings in Bioventus by 26.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 15,194 shares of the company's stock worth $160,000 after acquiring an additional 3,153 shares in the last quarter. Tower Research Capital LLC TRC increased its position in shares of Bioventus by 106.1% in the 4th quarter. Tower Research Capital LLC TRC now owns 3,469 shares of the company's stock valued at $36,000 after purchasing an additional 1,786 shares during the last quarter. Finally, Dimensional Fund Advisors LP raised its holdings in shares of Bioventus by 55.4% in the 4th quarter. Dimensional Fund Advisors LP now owns 427,422 shares of the company's stock valued at $4,488,000 after purchasing an additional 152,311 shares in the last quarter. 62.94% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, Canaccord Genuity Group reissued a "buy" rating and issued a $15.00 target price on shares of Bioventus in a report on Monday, March 17th.

Insider Activity

In other news, SVP Anthony D'adamio sold 4,380 shares of Bioventus stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $10.19, for a total transaction of $44,632.20. Following the sale, the senior vice president now owns 118,178 shares in the company, valued at approximately $1,204,233.82. The trade was a 3.57 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CFO Mark Leonard Singleton sold 3,875 shares of the business's stock in a transaction dated Friday, April 11th. The shares were sold at an average price of $7.57, for a total value of $29,333.75. Following the completion of the sale, the chief financial officer now directly owns 141,088 shares of the company's stock, valued at $1,068,036.16. The trade was a 2.67 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 24,208 shares of company stock worth $226,138. Corporate insiders own 32.90% of the company's stock.

Bioventus Stock Up 1.1 %

BVS traded up $0.08 on Friday, reaching $7.34. The company's stock had a trading volume of 377,946 shares, compared to its average volume of 454,672. The company has a quick ratio of 0.99, a current ratio of 1.41 and a debt-to-equity ratio of 1.85. Bioventus Inc. has a fifty-two week low of $3.94 and a fifty-two week high of $14.38. The stock has a 50 day moving average of $8.74 and a two-hundred day moving average of $10.31. The company has a market capitalization of $601.47 million, a price-to-earnings ratio of -12.03 and a beta of 0.92.

Bioventus Profile

Bioventus Inc, a medical device company, focuses on developing and commercializing treatments that engage and enhance the body's natural healing process in the United States and internationally. The company's product portfolio includes pain treatments, which comprise non-surgical pain injection therapies, as well as peripheral nerve stimulation products, such as Durolane, GELSYN-3, and SUPARTZ for the treatment of knee osteoarthritis and Stimrouter to treat chronic peripheral pain.